PUBLISHED PAPERS
Sustaining the benefits of intravenous ketamine with behavioural activation therapy for depression: A case series. Phillips JL, Blier P, Talbot J (2023). Journal of Affective Disorders Reports, 14:100613. doi: 10.1016/j.jadr.2023.100613.
Free-water diffusion magnetic resonance imaging differentiates suicidal ideation from suicide attempt in treatment-resistant depression. Vandeloo KL, Burhunduli P, Bouix S, Owsia K, Cho KIK, Fang Z, Van Geel A, Pasternak O, Blier P, Phillips JL (2023). Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 8(4):471-481. doi.org/10.1016/j.bpsc.2022.12.007.
A participant-level integrative data analysis of differential placebo response for suicidal ideation and non-suicidal depressive symptoms in clinical trials of intravenous racemic ketamine. Bloomfield-Clagett B, Ballard E, Greenstein D, Wilkinson S, Grunebaum M, Murrough J, Mathew S, Phillips JL, Fava M, Sanacora G, Zarate Jr. C (2022). International Journal of Neuropsychopharmacology, pyac055. doi:10.1093/ijnp/pyac055.
Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions. Phillips JL, Van Geel A, Burhunduli P, Vasudev D, Batten LA, Norris S, Talbot J, Ortiz A, Owoeye O, Blier P (2022). International Journal of Neuropsychopharmacology, pyac045. doi: 10.1093/ijnp/pyac045.
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Price RB, Kessel N, Baumeister A, Rohac R, Woody M, Ballard E, Zarate C, Deakin W, Abdallah C, Feder A, Grunebaum M, Mann J, Mathew SJ, McLoughlin D, Murrough J, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson S, Wallace ML (2022). Molecular Psychiatry, 27(12):5096-5112. doi:10.1038/s41380-022-01757-7.
Sex-differences in determinants of suicide risk preceding psychiatric admission: An electronic medical record study. McQuaid RJ, Nikolitch K, Vandeloo KL, Burhunduli P, Phillips JL (2022). Frontiers in Psychiatry, 13:892225. doi:10.3389/fpsyt.2022.892225.
The new frontline: Exploring the links between moral distress, moral resilience and mental health in healthcare workers amidst the COVID-19 pandemic. Spilg E, Rushton CH, Phillips JL, Kendzerska T, Saad M, Gifford W, Gautam M, Bhatla R, Edwards JD, Quilty L, Leveille C, Robillard R (2022). BMC Psychiatry, 22(1):1-12. doi:10.1186/s12888-021-03637-w.
Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression. de la Salle S, Phillips JL, Blier P, Knott K (2022). Progress in Neuropsychopharmacology and Biological Psychiatry, 110507. doi:10.1016/j.pnpbp.2021.110507.
Emerging new psychiatric symptoms and the worsening of pre-existing mental disorders during the COVID-19 pandemic: A Canadian multi-site case-control study. Robillard R, Daros A, Phillips JL, Pennestri M-H, Saad M, Kendzerska T, Edwards JD, Solomonova E, Porteous M, Bhatla R, Godbout R, Boafo A, Quilty L (2021). Canadian Journal of Psychiatry, 66(9):815-826. doi:10.1177/0706743720986786.
Social, financial and psychological stress during an emerging pandemic: observations from a population survey in the acute phase of COVID-19. Robillard R, Saad M, Edwards JD, Solomonova E, Pennestri M, Daros A, Veissière SPL, Quilty L, Dion K, Nixon A, Phillips JL, Bhatla R, Spilg E, Godbout R, Yazji B; Rushton CH, Gifford W, Gautam M, Boafo A, Kendzerska T (2020). BMJ Open, 10:e043805. doi:10.1136/bmjopen-2020-043805.
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian Biomarker Integration Network in Depression (CAN-BIND) study protocol. Phillips JL, Jaworska N, Kamler E, Bhat V, Blier J, Foster JA, Hassel S, Ho K, McMurray L, Milev R, Moazamigoudarzi Z, Placenza FM, Richard-Devantoy S, Rotzinger S, Turecki G, Vazquez GH, Kennedy SH, Blier P, and on behalf of the CAN-BIND Investigator Team (2020). BMC Psychiatry, 20:268. doi:10.1186/s12888-020-02672-3.
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, Owoeye A, Batten LA, Blier P (2020). Neuropsychopharmacology, 45(4):606-612. doi:10.1038/s41386-019-0570-x.
Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye A, Batten LA, Blier P (2020). Focus, 18(2):236-243. doi:10.1176/appi.focus.18206
Ketamine for chronic depression: Two cautionary tales. Talbot J, Phillips JL, Blier P (2019). Journal of Psychiatry and Neuroscience, 44(6):384-385. doi:10.1503/jpn.190073.
Harnessing neuroimaging to enhance our understanding of the effects of ketamine in depression. Jaworksa N, Phillips JL (2019). Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 4(7):603-605. doi:10.1016/j.bpsc.2019.05.005.
Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye A, Batten LA, Blier P (2019). American Journal of Psychiatry, 176(5):401-409. doi:10.1176/appi.ajp.2018.18070834.
Impact of monoamine-related gene polymorphisms on hippocampal volume in treatment-resistant depression. Phillips JL, Batten LA, Tremblay P, Aldosary F, Du L, Blier P (2015). Acta Neuropsychiatrica, 27(6):353-361. doi:10.1017/neu.2015.25.
A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. Phillips JL, Batten LA, Tremblay P, Aldosary F, Blier P (2015). International Journal of Neuropsychopharmacology, 18(8):1-9. doi:10.1093/ijnp/pyv037.
Structural hippocampal anomalies in a schizophrenia population correlate with navigation performance on a wayfinding task. Ledoux A-A, Boyer P, Phillips JL, Labelle A, Smith A, Bohbot VD (2014). Frontiers in Behavioral Neuroscience, 8(88):1-11. doi:10.3389/fnbeh.2014.00088.
Ms. Phillips and Dr. Blier reply [Letter to the editor]. Phillips JL, Blier P. (2013). Journal of Clinical Psychiatry, 74(6):631-632. doi:10.4088/JCP.12lr08004a.
Decreased fMRI activity in the hippocampus of patients with schizophrenia compared to healthy control participants, tested on a wayfinding task in a virtual town. Ledoux A-A, Phillips JL, Labelle A, Smith A, Bohbot VD, Boyer P (2013). Psychiatry Research: Neuroimaging, 211(1):47-56. doi:10.1016/j.pscychresns.2012.10.005.
Manipulating subjective realism and its impact on presence: Preliminary results on feasibility and neuroanatomical correlates. Bouchard S, Dumoulin S, Talbot J, Ledoux A-A, Phillips JL, Monthuy-Blanc J, Labonté-Chartrand G, Robillard G, Cantamesse M, Renaud P (2012). Interacting with Computers, 24(4):227-236. doi:10.1016/j.intcom.2012.04.011.
Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. Phillips JL, Batten LA, Aldosary F, Tremblay P, Blier P (2012). Journal of Clinical Psychiatry, 73(5):625-631. doi:10.4088/JCP.11m06865.
Presence is just an illusion: using fMRI to locate the brain area responsible to the meaning given to places. Bouchard S, Talbot J, Ledoux A-A, Phillips JL, Cantamesse M, Robillard G (2010). Studies in Health Technology and Informatics, 154:193-196. PMID: 20543296. doi:10.3233/978-1-60750-561-7-193.
The meaning of being there is related to a specific activation in the brain located in the parahippocampus. Bouchard S, Talbot J, Ledoux A-A, Phillips JL, Cantamese M, Robillard G (2009). International Society for Presence Research, 1:1-6. ISBN:978-0-9792217-3-6.
Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Boyer P, Phillips JL, Rousseau FL, Ilivitsky S (2007). Brain Research Reviews, 54(1):92-112. doi:10.1016/j.brainresrev.2006.12.008.